Skip to main content

and
  1. Article

    Open Access

    Long-Term Effectiveness and Safety of Ixekizumab for the Treatment of Moderate-to-Severe Plaque Psoriasis: A Five-Year Multicenter Retrospective Study—IL PSO (Italian Landscape Psoriasis)

    The introduction of biological therapies has revolutionized the treatment of moderate-to-severe plaque psoriasis. In particular, ixekizumab, an inhibitor of interleukin-17A, has shown great results in terms of...

    Mario Valenti, Luigi Gargiulo, Luciano Ibba in Dermatology and Therapy (2024)

  2. Article

    Open Access

    Correction to: AtopyReg®, the Prospective Italian Patient Registry for Moderate-to-Severe Atopic Dermatitis in Adults: Baseline Demographics, Disease Characteristics, Comorbidities, and Treatment History

    Luca Stingeni, Andrea Chiricozzi in American Journal of Clinical Dermatology (2024)

  3. Article

    Open Access

    AtopyReg®, the Prospective Italian Patient Registry for Moderate-to-Severe Atopic Dermatitis in Adults: Baseline Demographics, Disease Characteristics, Comorbidities, and Treatment History

    AtopyReg® is a multicenter, prospective, observational, non-profit cohort study on moderate-to-severe atopic dermatitis in adults promoted in 2018 by the Italian Society of Dermatology and Venereology (SIDeMaST)....

    Luca Stingeni, Andrea Chiricozzi in American Journal of Clinical Dermatology (2024)

  4. Article

    Extracutaneous involvement of pyoderma gangrenosum

    Pyoderma Gangrenosum (PG) is an inflammatory neutrophilic dermatosis (ND) associated with underlying chronic inflammation and/or malignancy. Diagnosis remains to be challenging as a gold standard diagnostic te...

    Luis J. Borda, Lulu L. Wong, Angelo V. Marzano in Archives of Dermatological Research (2019)

  5. No Access

    Article

    PAPA, PASH and PAPASH Syndromes: Pathophysiology, Presentation and Treatment

    Pyoderma gangrenosum (PG) is a neutrophilic dermatosis usually manifesting as skin ulcers with undermined erythematous-violaceous borders. It may be isolated, associated with systemic conditions or occurring i...

    Massimo Cugno, Alessandro Borghi in American Journal of Clinical Dermatology (2017)

  6. No Access

    Reference Work Entry In depth

    Langerhans Cell Histiocytosis, Skin

    Emilio Berti, Angelo V. Marzano in Dermatopathology (2016)

  7. No Access

    Article

    Pathomechanisms of Chronic Spontaneous Urticaria: What Is Known and Up to Date

    The pathomechanism of chronic spontaneous urticaria (CSU), defined by the recurrence of short-lived wheals for more than 6 weeks without apparent triggers, remained to be mysterious until 1986. In that year, s...

    Riccardo Asero, Alberto Tedeschi, Angelo V. Marzano in Current Dermatology Reports (2014)

  8. Article

    Chronic Spontaneous Urticaria: the Emerging Role of Coagulation

    Chronic urticaria (CU) is a cutaneous disease characterized by the recurrent eruption of short-lived wheals for at least six weeks. The wheals, which are surface swelling of the dermis accompanied by itching, ...

    Angelo V. Marzano, Alberto Tedeschi, Claudia Menicanti in Current Dermatology Reports (2013)